Risperidone Articles
Janssen to pay $181 million in Risperdal settlement
31 August 2012
New briefs: GSK extends HGS tender offer; J&J plans for $600 million charge; FDA delays prophylactic Truvada
10 June 2012
News briefs on Janssen, Bayer and Merck KGaA/Threshold
12 April 2012
Merck & Co and Johnson & Johnson settlements
20 January 2012
US approval of generic Protonix for Actavis and Risperdal for Taro; Watson does not infringe patent
10 February 2011
Alkermes shrugs off Bydureon and focuses on pipeline, company reveals in interview with EP Vantage
15 November 2010
Johnson & Johnson’s 4th-qtr/full year 2009 sales and profit exceed expectations, but forecast disappoints
27 January 2010
Double whammy for Johnson & Johnson, as DoJ sues on alleged “kickbacks,” and Tylenol contamination discovered
18 January 2010
Johnson & Johnson to shed 6%-7% of jobs; confirms 2009 guidance
4 November 2009
Atypical antipsychotics cause significant weight gain in children and young adults, JAMA study reports
28 October 2009
Johnson & Johnson’s 3rd quarter disappoints, as generics gouge leading drugs, though cost cuts help profits
14 October 2009
J&J decision to halt risperidone inj a setback for Alkermes’ pipeline, say analysts
1 September 2009
Stock Commentary - New York week to June 1, 2009
4 June 2009
J&J/Alkermes' Risperdal Consta approved in Japan
30 April 2009
J&J 1st qtr hit by market drop; keeps guidance
15 April 2009
Janssen Japan down on end of KHK deal
14 April 2009
FDA panel backs limited use of Serdolect
8 April 2009
FDA cardiac concerns on Lundbeck's Serdolect
7 April 2009
Ranbaxy plant OKed by UK/Australian agencies
30 March 2009
J&J to pay $4.5M for "misleading physicians"
9 March 2009
Corlux plus Risperdal results in less abdominal fat
2 March 2009
FDA wants more data on J&J and Alkermes' Risperdal Consta
16 February 2009
J&J seeking to enlarge paliperidone franchise
16 February 2009
Corlux mitigates Risperdal weight gain
9 February 2009
J&J's paliperidone LA shows 13-week control
22 December 2008
J&J unit "tapped" for funds by pediatrician
8 December 2008
FDA approval for new Risperdal injection site
20 October 2008
SPD Minister attacks Germany's drugmakers
29 September 2008
Mylan's generic Risperdal cleared by FDA
22 September 2008
Syntropharma raises $2.4M in second round of investment
15 September 2008
Teva's 2nd-qtr 2008 profit up 5% to $539M
18 August 2008
Vanda's shares halve on US iloperidone setback
4 August 2008
Japan stock market week to July 21, 2008
28 July 2008
Alkermes' fiscal-2008 income soars on Reliant
9 June 2008
J&J drug: longer time to relapse than quetiapine
12 May 2008
Promotional spending on atypical antipsychotice analyzed
17 March 2008
UPDATE: GPhA sees US prospects in 2008, Rx share at 65%
25 February 2008
Generic Rxing hits 65% of US market
25 February 2008
Reliant sale boosts Alkermes 3rd-qtr EPS
18 February 2008
J&J's 4th-qtr 2007 sales jump 16.6%, EPS up 11%
28 January 2008
German generics see drug majors cut prices
14 January 2008
Japan stock market week to Dec 3, 2007
10 December 2007
Charges hit J&J's third qtr; forecast raised
22 October 2007
Patent expiries will reduce bipolar drug market $400M
1 October 2007
Janssen and AstraZeneca drugs now lead antipsychotics
24 September 2007
FDA clears Risperdal for two new indications
3 September 2007
Seroquel as effective as olanzapine in mania
3 September 2007
Alkermes sees fiscal 1st-qtr net income of $8.7M
13 August 2007
J&J's 2nd-qtr 2007 net income jumps 9.2%
23 July 2007
FDA "approvable" letter for J&J's Risperdal sNDAs
25 June 2007
Barr's generic Risperdal gets tentative US approval
11 June 2007
Vanda's iloperidone shows good akathisia profile
4 June 2007
FDA approves new Risperdal Consta dose
23 April 2007
UK AD patients face sedative death risk
9 April 2007
ACP-103 cuts PNSS score in Ph II trial
26 March 2007
J&J subsids receive three US subpoenas
19 March 2007
Alkermes reports $3M 4th-qtr 2006 net income
19 February 2007
J&J's 4th qtr 2006 EPS beats analysts' estimate
29 January 2007
Lilly maintains cost-effectiveness of Zyprexa
11 December 2006
Japan's generic drugs market expected to grow 8.8% from 2006 to 2008
27 November 2006
NAA urges caution of Risperdal's side effects
30 October 2006
J&Js 3rd-qtr profit rises 8.7% to $2.76B
23 October 2006
Tentative FDA OK for Teva's risperidone
23 October 2006
FDA approves Risperdal for autistic irritability
16 October 2006
Israeli NHI Ombudswoman's complaints report
4 September 2006
J&J's record 2nd-qtr 2006 sales boost profit 10%
24 July 2006
Drug studies "biased" towards sponsors
24 April 2006
J&J still under probe
3 April 2006
Strong results for B-MS/Otsuka's Abilify
20 March 2006
Akzo 2005 income rises 1.7%, Organon gains
13 February 2006
J&J's 4th-qtr 2005 sales drop 1.1% on low Rx
30 January 2006
Quetiapine efficacy equal to risperidone
9 January 2006
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
